Immunotherapy of B-cell non-Hodgkin lymphoma by targeting the chemokine receptor CXCR5 in a preclinical mouse model

International Journal of Cancer

Volumn 135, Issue 11, 2014, Pages 2623-2632

  Panjideh, Hossein ^a   Muller, Gerd ^a   Koch, Mathias ^a   Wilde, Frank ^a   Scheu, Susanne ^a   Moldenhauer, Gerhard ^b   Lipp, Martin ^a  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Bispecific antibody; CD3; Chemokine receptor; CXCR5; Immunotherapy; Non Hodgkin lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; CD19::CD3 ANTIBODY; CD3 ANTIBODY; CD3 ANTIGEN; CD69 ANTIGEN; CHEMOKINE RECEPTOR CXCR5; CHEMOKINE RECEPTOR CXCR5 CD3 ANTIBODY; CXCR5 ANTIBODY; CXCR5::CD3 ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; B CELL NONHODGKIN LYMPHOMA; B LYMPHOCYTE; CANCER CELL LINE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MATURATION; CONTROLLED STUDY; CYTOKINE RELEASE; DEPLETION; DRUG CYTOTOXICITY; DRUG EFFICACY; EFFECTOR CELL; FEMALE; HELPER CELL; HOMEOSTASIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; LYMPHOMA CELL; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; QUADROMA CELL LINE; RAJI BURKITT LYMPHOMA CELL; T LYMPHOCYTE; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DISEASE MODEL; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOMA, B-CELL; METABOLISM; MORTALITY; NONOBESE DIABETIC MOUSE; PATHOLOGY; SCID MOUSE; SURVIVAL RATE; TUMOR CELL CULTURE; XENOGRAFT;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIGENS, CD3; B-LYMPHOCYTES; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOTHERAPY; LYMPHOMA, B-CELL; MICE; MICE, INBRED NOD; MICE, SCID; RECEPTORS, CXCR5; SURVIVAL RATE; T-LYMPHOCYTES; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 84921672369     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28893     Document Type: Article

References (30)

1. Maloney DG. Anti-CD20 antibody therapy for Bcell lymphomas. N Engl J Med 2012;366:2008-16.
2. Rezvani AR, Maloney DG. Rituximab resistance. Best Pract Res Clin Haematol 2011;24:203-16.
3. Riesenberg R, Buchner A, Pohla H, et al. Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3). J Histochem Cytochem 2001;49:911-7.
4. Zeidler R, Mysliwietz J, Csanady M, et al. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer 2000;83:261-6.
5. May C, Sapra P, Gerber HP. Advances in bispecific biotherapeutics for the treatment of cancer. Biochem Pharmacol 2012;84:1105-12.
6. Chames P, Baty D. Bispecific antibodies for cancer therapy: the light at the end of the tunnel? MAbs 2009;1:539-47.
7. Gao Y, Xiong D, Yang M, et al. Efficient inhibition of multidrug-resistant human tumors with a recombinant bispecific anti-P-glycoprotein x anti-CD3 diabody. Leukemia 2004;18:513-20.
8. Dobner T, Wolf I, Emrich T, et al. Differentiation-specific expression of a novel G proteincoupled receptor from Burkitt's lymphoma. Eur J Immunol 1992;22:2795-9.
9. Burkle A, Niedermeier M, Schmitt-Graff A, et al. Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. Blood 2007;110:3316-25.
10. Breitfeld D, Ohl L, Kremmer E, et al. Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J Exp Med 2000;192:1545-52.
11. Forster R, Emrich T, Kremmer E, et al. Expression of the G-protein-coupled receptor BLR1 defines mature, recirculating B cells and a subset of T-helper memory cells. Blood 1994;84:830-40.
12. Rasheed AU, Rahn HP, Sallusto F, et al. Follicular B helper T cell activity is confined to CXCR5(hi)ICOS(hi) CD4 T cells and is independent of CD57 expression. Eur J Immunol 2006;36:1892-903.
13. Meijer J, Zeelenberg IS, Sipos B, et al. The CXCR5 chemokine receptor is expressed by carcinoma cells and promotes growth of colon carcinoma in the liver. Cancer Res 2006;66:9576-82.
14. Chunsong H, Yuling H, Li W, et al. CXC chemokine ligand 13 and CC chemokine ligand 19 cooperatively render resistance to apoptosis in B cell lineage acute and chronic lymphocytic leukemia CD231CD51 B cells. J Immunol 2006;177:6713-22.
15. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer 2012;12:278-87.
16. Loffler A, Gruen M, Wuchter C, et al. Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Leukemia 2003;17:900-9.
17. Norman DJ. Mechanisms of action and overview of OKT3. Ther Drug Monit 1995;17:615-20.
18. StanglmaierM, FaltinM, Ruf P, et al. Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels. Int J Cancer 2008;123:1181-9.
19. Wimberger P, Gilet H, Gonschior AK, et al. Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone. Ann Oncol 2012;23:1979-85.
20. Heiss MM, Murawa P, Koralewski P, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer 2010;127:2209-21.
21. Lindhofer H, Mocikat R, Steipe B, et al. Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a singlestep purification of bispecific antibodies. J Immunol 1995;155:219-25.
22. Csoka M, Strauss G, Debatin KM, et al. Activation of T cell cytotoxicity against autologous common acute lymphoblastic leukemia (cALL) blasts by CD3xCD19 bispecific antibody. Leukemia 1996;10:1765-72.
23. Daniel PT, Kroidl A, Kopp J, et al. Immunotherapy of B-cell lymphoma with CD3x19 bispecific antibodies: costimulation via CD28 prevents "veto" apoptosis of antibody-targeted cytotoxic T cells. Blood 1998;92:4750-7.
24. Dreier T, Baeuerle PA, Fichtner I, et al. T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3-bispecific singlechain antibody construct. J Immunol 2003;170: 4397-402.
25. Dyer MJ, Hale G, Hayhoe FG, et al. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 1989;73:1431-9.
26. Cragg MS, French RR, Glennie MJ. Signaling antibodies in cancer therapy. Curr Opin Immunol 1999;11:541-7.
27. Zeidler R, Mayer A, Gires O, et al. TNFalpha contributes to the antitumor activity of a bispecific, trifunctional antibody. Anticancer Res 2001; 21:3499-503.
28. Heiss MM, Strohlein MA, Jager M, et al. Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer 2005;117: 435-43.
29. Chelius D, Ruf P, Gruber P, et al. Structural and functional characterization of the trifunctional antibody catumaxomab. MAbs 2010;2: 309-19.
30. Bagaeva LV, Rao P, Powers JM, et al. CXC chemokine ligand 13 plays a role in experimental autoimmune encephalomyelitis. J Immunol 2006; 176:7676-85.